Retatrutide UK: Research, Legal Status & Where It Stands in 2026

Retatrutide is an investigational once-weekly peptide developed by Eli Lilly that activates three hormone receptors at once: GIP, GLP-1 and glucagon. In the UK it has no MHRA marketing authorisation and is not available as a medicine; it is supplied only as a laboratory research chemical. Its phase 2 trial (Jastreboff et al., NEJM 2023) reported a mean weight reduction of 24.2% at 48 weeks, and the 2026 TRIUMPH phase 3 readouts have pushed that figure to 28.3% at 80 weeks and 30.3% at 104 weeks. This guide covers the science, the trial data and the legal position for anyone researching retatrutide in the UK.

What is retatrutide?

Retatrutide (development code LY3437943) is a single 39-amino-acid peptide engineered to bind to the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is often described as a "triple agonist" or, informally, as "GLP-3", though that nickname is not a scientific term.

The rationale behind the design is that each receptor contributes something different. GLP-1 activation is studied for its effects on appetite and gastric emptying; GIP activation appears to enhance those effects and may improve tolerability; and glucagon receptor activation is investigated for increasing energy expenditure and reducing liver fat. Semaglutide acts on one of these receptors and tirzepatide on two; retatrutide is the first compound to reach late-stage trials acting on all three.

Like other incretin-class peptides, retatrutide is modified with a fatty-acid side chain that binds to albumin in the blood, extending its half-life to roughly six days and allowing once-weekly administration in the trial programme.

The research so far: from phase 2 to TRIUMPH

The pivotal early data came from a 48-week phase 2 trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.). It enrolled 338 adults with obesity or overweight and tested weekly doses from 1 mg to 12 mg against placebo. At 48 weeks, participants in the 12 mg group had lost a mean of 24.2% of body weight, compared with about 2% on placebo, and the weight-loss curves had not plateaued when the trial ended. A parallel phase 2 in adults with type 2 diabetes, published in The Lancet the same year, reported both weight reduction and improvements in HbA1c.

Lilly then launched the TRIUMPH phase 3 programme, a set of large trials covering obesity with and without diabetes, knee osteoarthritis, cardiovascular disease and other complications. The first pivotal readout, TRIUMPH-1, was announced in May 2026: in 2,339 adults without diabetes, retatrutide produced an average 28.3% weight reduction at 80 weeks, and participants who continued on the 12 mg dose to 104 weeks averaged 30.3%, with no plateau observed. The trial also reported meaningful reductions in knee osteoarthritis pain in the relevant sub-study.

In July 2026, TRIUMPH-2 and TRIUMPH-3 followed. These enrolled adults with obesity and type 2 diabetes, and adults with obesity and established cardiovascular disease, respectively. Both met their primary endpoints, with weight reductions of up to 22.6%, alongside reductions in HbA1c, non-HDL cholesterol and systolic blood pressure. Several further TRIUMPH readouts, including maintenance-dosing studies, are expected through the rest of 2026.

Retatrutide UK legal status: no MHRA licence

Retatrutide has not been granted a marketing authorisation by the MHRA, the European Medicines Agency or the US FDA. It cannot be prescribed in the UK, is not stocked by pharmacies, and is not available on the NHS or privately as a medicine. Any website offering "retatrutide for weight loss" to UK consumers is supplying an unlicensed medicine in breach of the Human Medicines Regulations 2012.

What is lawful is the supply and possession of retatrutide as a research chemical. The compound is not controlled under the Misuse of Drugs Act 1971, so buying it, holding it and using it in laboratory research is legal, provided it is sold and labelled strictly for research and not presented for human use. Our article on whether peptides are legal in the UK explains that distinction in full.

Lilly has said it intends to begin regulatory submissions once the TRIUMPH programme has read out. No UK filing or MHRA decision date has been confirmed at the time of writing, and the earliest any licensed retatrutide product could realistically reach UK patients is well after the full phase 3 dataset is in.

How retatrutide compares with licensed UK medicines

The UK currently has two licensed injectable weight-management medicines in this class: semaglutide (Wegovy) and tirzepatide (Mounjaro). Both are prescription-only, both are MHRA-authorised, and both are available through the NHS in limited circumstances and through private prescribers. In their pivotal trials, semaglutide 2.4 mg produced a mean 14.9% weight reduction at 68 weeks (STEP 1), and tirzepatide up to 20.9% at 72 weeks (SURMOUNT-1).

Retatrutide's numbers are larger, but they come from different trials with different populations and durations, so the comparison is indicative rather than direct. The important practical point for a UK reader is regulatory: semaglutide and tirzepatide are medicines you can be prescribed; retatrutide is not. Our retatrutide vs tirzepatide article sets the two side by side.

Buying retatrutide in the UK for research: what to check

Because retatrutide is in such demand, it is also one of the most frequently counterfeited or underdosed research peptides. The safeguards are the same as for any research chemical, but they matter more here.

• Batch-specific certificate of analysis from an independent laboratory. Calibre retatrutide batches are tested by Janoshik Analytical and the COAs are published on the site's COA page.
• HPLC purity above 99% and a mass spectrometry result matching retatrutide's theoretical molecular mass (approximately 4,731 Da).
• Quantity verification: a 10 mg pen should contain close to 10 mg of peptide, and the COA should say so.
• Format and strength that suit the work. Calibre supplies pre-filled, precision-made retatrutide pens at 10, 20, 30 and 40 mg.
• A UK-based supplier with a named team and reachable support, rather than an anonymous overseas storefront.
• No health claims, dosing guidance or "protocols" on the product page. If they are there, the seller is operating unlawfully and the product is unlikely to be what it says it is.

Safety signals reported in the trials

Across the phase 2 and phase 3 programme, the most commonly reported adverse events were gastrointestinal: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate and most frequent during dose escalation. In the NEJM phase 2, discontinuation due to adverse events ranged from roughly 6% to 16% across retatrutide arms. TRIUMPH-1 reported that gastrointestinal events were generally mild and infrequently led to discontinuation.

Investigators have also noted increases in heart rate during the early weeks of treatment, consistent with other incretin-class compounds, and dose-dependent changes in skin sensation (dysaesthesia) reported in a minority of participants in phase 2. These are trial findings reported in the third person; they do not translate into any guidance for research material, which is not for human use.

What is being studied beyond weight

The glucagon receptor component makes retatrutide interesting in liver research. A phase 2 sub-study reported large reductions in liver fat in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), and dedicated trials in that population are under way. TRIUMPH-1 included a knee osteoarthritis cohort, and Lilly is running studies in chronic kidney disease, obstructive sleep apnoea and cardiovascular outcomes.

For laboratories, this breadth is why retatrutide is one of the most requested research peptides in the UK. Receptor-selectivity work, comparative pharmacology against single and dual agonists, and analytical method development all draw on well-characterised research-grade material.